Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman bought 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 26th. The stock was acquired at an average price of $3.61 per share, with a total value of $19,133.00. Following the completion of the purchase, the chief executive officer now directly owns 11,166 shares of the company’s stock, valued at approximately $40,309.26. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) traded down $0.22 during trading hours on Friday, reaching $3.45. The company’s stock had a trading volume of 122,165 shares, compared to its average volume of 59,969. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $2.85 and a 12 month high of $9.40.
TNXP has been the subject of several research analyst reports. ValuEngine lowered Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, October 2nd. Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $8.33.
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. B. Riley Financial Inc. purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 378,138 shares of the company’s stock, valued at approximately $1,637,000. B. Riley Financial Inc. owned about 5.05% of Tonix Pharmaceuticals at the end of the most recent reporting period. 17.57% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://transcriptdaily.com/2017/12/31/insider-buying-tonix-pharmaceuticals-holding-corp-tnxp-ceo-acquires-19133-00-in-stock.html.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.